37663-44-8|3H-Spiro[isobenzofuran-1,4'-piperidine] hydrochloride| Ambeed

Size	Price	VIP Price	US Stock	Global Stock	In Stock
{[ item.pr_size ]}		Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

{[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

Quality Control of [ 37663-44-8 ] Purity: 95% SDS Specification

COA

Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.

NMR

Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.

CNMR

Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.

HPLC

Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.

LC-MS

Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.

1-2 Day Shipping
High Quality
Technical Support

Product Details of [ 37663-44-8 ]

CAS No. :	37663-44-8
Formula :	C₁₂H₁₆ClNO
M.W :	225.71
SMILES Code :	[H]Cl.C12=C(C3(CCNCC3)OC2)C=CC=C1
MDL No. :	MFCD02179146
InChI Key :	SFQFBDOOIIHNMY-UHFFFAOYSA-N
Pubchem ID :	22509330

Safety of [ 37663-44-8 ]

GHS Pictogram:
Signal Word:	Warning
Hazard Statements:	H302-H315-H319-H332-H335
Precautionary Statements:	P261-P280-P305+P351+P338

Computational Chemistry of [ 37663-44-8 ] Show Less

Physicochemical Properties

Num. heavy atoms	15
Num. arom. heavy atoms	6
Fraction Csp3	0.5
Num. rotatable bonds	0
Num. H-bond acceptors	2.0
Num. H-bond donors	1.0
Molar Refractivity	66.02
TPSA ? Topological Polar Surface Area: Calculated from Ertl P. et al. 2000 J. Med. Chem.	21.26 Å²

Lipophilicity

Log P_o/w (iLOGP)? iLOGP: in-house physics-based method implemented from Daina A et al. 2014 J. Chem. Inf. Model.	0.0
Log P_o/w (XLOGP3)? XLOGP3: Atomistic and knowledge-based method calculated by XLOGP program, version 3.2.2, courtesy of CCBG, Shanghai Institute of Organic Chemistry	1.86
Log P_o/w (WLOGP)? WLOGP: Atomistic method implemented from Wildman SA and Crippen GM. 1999 J. Chem. Inf. Model.	1.96
Log P_o/w (MLOGP)? MLOGP: Topological method implemented from Moriguchi I. et al. 1992 Chem. Pharm. Bull. Moriguchi I. et al. 1994 Chem. Pharm. Bull. Lipinski PA. et al. 2001 Adv. Drug. Deliv. Rev.	2.02
Log P_o/w (SILICOS-IT)? SILICOS-IT: Hybrid fragmental/topological method calculated by FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com	2.78
Consensus Log P_o/w? Consensus Log P_o/w: Average of all five predictions	1.72

Water Solubility

Log S (ESOL):? ESOL: Topological method implemented from Delaney JS. 2004 J. Chem. Inf. Model.	-2.71
Solubility	0.443 mg/ml ; 0.00196 mol/l
Class? Solubility class: Log S scale Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly	Soluble
Log S (Ali)? Ali: Topological method implemented from Ali J. et al. 2012 J. Chem. Inf. Model.	-1.93
Solubility	2.67 mg/ml ; 0.0118 mol/l
Class? Solubility class: Log S scale Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly	Very soluble
Log S (SILICOS-IT)? SILICOS-IT: Fragmental method calculated by FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com	-3.84
Solubility	0.0326 mg/ml ; 0.000145 mol/l
Class? Solubility class: Log S scale Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly	Soluble

Pharmacokinetics

GI absorption? Gatrointestinal absorption: according to the white of the BOILED-Egg	High
BBB permeant? BBB permeation: according to the yolk of the BOILED-Egg	Yes
P-gp substrate? P-glycoprotein substrate: SVM model built on 1033 molecules (training set) and tested on 415 molecules (test set) 10-fold CV: ACC=0.72 / AUC=0.77 External: ACC=0.88 / AUC=0.94	Yes
CYP1A2 inhibitor? Cytochrome P450 1A2 inhibitor: SVM model built on 9145 molecules (training set) and tested on 3000 molecules (test set) 10-fold CV: ACC=0.83 / AUC=0.90 External: ACC=0.84 / AUC=0.91	No
CYP2C19 inhibitor? Cytochrome P450 2C19 inhibitor: SVM model built on 9272 molecules (training set) and tested on 3000 molecules (test set) 10-fold CV: ACC=0.80 / AUC=0.86 External: ACC=0.80 / AUC=0.87	No
CYP2C9 inhibitor? Cytochrome P450 2C9 inhibitor: SVM model built on 5940 molecules (training set) and tested on 2075 molecules (test set) 10-fold CV: ACC=0.78 / AUC=0.85 External: ACC=0.71 / AUC=0.81	No
CYP2D6 inhibitor? Cytochrome P450 2D6 inhibitor: SVM model built on 3664 molecules (training set) and tested on 1068 molecules (test set) 10-fold CV: ACC=0.79 / AUC=0.85 External: ACC=0.81 / AUC=0.87	Yes
CYP3A4 inhibitor? Cytochrome P450 3A4 inhibitor: SVM model built on 7518 molecules (training set) and tested on 2579 molecules (test set) 10-fold CV: ACC=0.77 / AUC=0.85 External: ACC=0.78 / AUC=0.86	Yes
Log Kp (skin permeation)? Skin permeation: QSPR model implemented from Potts RO and Guy RH. 1992 Pharm. Res.	-6.36 cm/s

Druglikeness

Lipinski? Lipinski (Pfizer) filter: implemented from Lipinski CA. et al. 2001 Adv. Drug Deliv. Rev. MW ≤ 500 MLOGP ≤ 4.15 N or O ≤ 10 NH or OH ≤ 5	0.0
Ghose? Ghose filter: implemented from Ghose AK. et al. 1999 J. Comb. Chem. 160 ≤ MW ≤ 480 -0.4 ≤ WLOGP ≤ 5.6 40 ≤ MR ≤ 130 20 ≤ atoms ≤ 70	None
Veber? Veber (GSK) filter: implemented from Veber DF. et al. 2002 J. Med. Chem. Rotatable bonds ≤ 10 TPSA ≤ 140	0.0
Egan? Egan (Pharmacia) filter: implemented from Egan WJ. et al. 2000 J. Med. Chem. WLOGP ≤ 5.88 TPSA ≤ 131.6	0.0
Muegge? Muegge (Bayer) filter: implemented from Muegge I. et al. 2001 J. Med. Chem. 200 ≤ MW ≤ 600 -2 ≤ XLOGP ≤ 5 TPSA ≤ 150 Num. rings ≤ 7 Num. carbon > 4 Num. heteroatoms > 1 Num. rotatable bonds ≤ 15 H-bond acc. ≤ 10 H-bond don. ≤ 5	0.0
Bioavailability Score? Abbott Bioavailability Score: Probability of F > 10% in rat implemented from Martin YC. 2005 J. Med. Chem.	0.55

Medicinal Chemistry

PAINS? Pan Assay Interference Structures: implemented from Baell JB. & Holloway GA. 2010 J. Med. Chem.	0.0 alert
Brenk? Structural Alert: implemented from Brenk R. et al. 2008 ChemMedChem	0.0 alert: heavy_metal
Leadlikeness? Leadlikeness: implemented from Teague SJ. 1999 Angew. Chem. Int. Ed. 250 ≤ MW ≤ 350 XLOGP ≤ 3.5 Num. rotatable bonds ≤ 7	No; 1 violation:MW<1.0
Synthetic accessibility? Synthetic accessibility score: from 1 (very easy) to 10 (very difficult) based on 1024 fragmental contributions (FP2) modulated by size and complexity penaties, trained on 12'782'590 molecules and tested on 40 external molecules (r² = 0.94)	2.35

Application In Synthesis of [ 37663-44-8 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

Upstream synthesis route of [ 37663-44-8 ]
Downstream synthetic route of [ 37663-44-8 ]

[ 37663-44-8 ] Synthesis Path-Upstream 1~1

1
[ 54596-09-7 ]
[ 37663-44-8 ]

References: [1] Patent: EP1726590, 2006, A1, . Location in patent: Page/Page column 49-50.

[ 37663-44-8 ] Synthesis Path-Downstream 1~27

1
[ 19997-52-5 ]
[ 37663-44-8 ]
[ 54596-10-0 ]

References: [1]Journal of Organic Chemistry,1975,vol. 40,p. 1427 - 1433.

2
[ 37663-44-8 ]
[ 3874-54-2 ]
[ 56657-97-7 ]

References: [1]Journal of Organic Chemistry,1975,vol. 40,p. 1427 - 1433.

3
[ 749898-77-9 ]
[ 37663-44-8 ]
[ 749913-55-1 ]

Yield	Reaction Conditions	Operation in experiment
	With N-ethyl-N,N-diisopropylamine; In 1-methyl-pyrrolidin-2-one; at 120℃; for 6h;	The product from example 2 step a) (O. LG) and 4-spiro [ISOBENZOFURAN-1 (3H), 4'- piperidine] hydrochloride (0. 11 G) IN NMP (2ML) and Hunigs base (0. 2ML) were heated at 120 C for 6h. The resulting mixture was cooled, diluted with methanol (3ml), filtered and the filtrate was purified by reverse phase HPLC (Symmetry column, gradient 95- 50percent aqueous, ammonium acetate (0.2percent aq. ) in acetonitrile) to yield the title compound as a buff solid (44mg). MS (APCI+) 398/400 [M+H] + 'H NMR 6 (DMSO) 8.41 (d, LH), 7.93 (d, LH), 7. 30 (s, 4H), 5.04 (s, 2H), 3.90 (d, 2H), 3.48 (dt, 2H), 3.23 (dd, 4H), 2.06 (td, 2H), 1.85 (s, 4H), 1.76 (d, 2H)

References: [1]Patent: WO2004/74273,2004,A1 .Location in patent: Page 20.

4
[ 37663-44-8 ]
[ 273756-96-0 ]
[ 741683-25-0 ]

Yield	Reaction Conditions	Operation in experiment
	With potassium carbonate; potassium iodide; In DMF (N,N-dimethyl-formamide); at 80℃; for 18h;	To a solution of above compound (5.00 g) in DMF (50 ml), spiro[isobenzofuran-1(3H), 4'-piperidine] hydrochloride (4.22 g), potassium carbonate (12.92 g) and potassium iodide (310 g) were added by the order stated, and stirred for 18 hours at 80°C. The reaction liquid was cooled to room temperature, to which water was added, followed by extraction with ethyl acetate. The organic layer was washed with saturated brine, dried over anhydrous sodium sulfate and condensed under reduced pressure. The resulting residue was purified on silica gel column chromatography (methanol/ethyl acetate = 1/9) to provide tert-butyl N-methyl-N-[3-(spiro[isobenzofuran-1(3H), 4'-piperidin]-1-yl)propyl]- carbamate (4.71 g) as a pale yellow oily substance.

References: [1]Patent: EP1595867,2005,A1 .Location in patent: Page/Page column 36.

5
[ 3783-77-5 ]
[ 37663-44-8 ]
[ 475152-37-5 ]

Yield	Reaction Conditions	Operation in experiment
		To a solution of spiro[isobenzofuran-1(3H), 4'-piperidine] hydrochloride (2.80 g) and 2-(3-oxobutyl)-1H-isoindol-1,3(2H)-dione (2.0 g) in THF-methanol (1:1 v/v, 40 ml), 0.3 M sodium cyanoborohydride-1/2 zinc chloride solution in methanol (44 ml) was added and stirred for 20 hours at room temperature. Saturated aqueous sodium hydrogencarbonate solution was added to the reaction liquid, followed by extraction with ethyl acetate. The organic layer was washed with saturated brine, dried over anhydrous sodium sulfate and condensed under reduced pressure. The resulting solid was washed with a small amount of methanol to provide 2-(3-spiro[isobenzofuran-1(3H), 4'-piperidin-1-yl]butyl-1H-isoindol-1, 3(2H)-dione (578 mg) as a white solid.

References: [1]Patent: EP1595867,2005,A1 .Location in patent: Page/Page column 48.

6
[ 37663-44-8 ]
[ 135614-99-2 ]
[ 741683-27-2 ]

Yield	Reaction Conditions	Operation in experiment
	With potassium carbonate; In DMF (N,N-dimethyl-formamide); at 100℃; for 18h;	To a solution of tert-butyl N-methyl-N-(2-oxylanylmethyl) carbamate (300 mg) in DMF (3 ml), spiro[isobenzofuran-1(3), 4'-piperidine] hydrochloride (326 mg) and potassium carbonate (332 mg) were added and stirred for 18 hours at 100°C. The reaction liquid was cooled to room temperature and to which water was added, followed by extraction with ethyl acetate. The organic layer was washed with saturated brine, dried over anhydrous sodium sulfate and condensed under reduced pressure. The resulting residue was purified on silica gel column chromatography (methanol/chloroform = 1/20) to provide tert-butyl N-methyl-N-(2-hydroxy-3-(spiro- [isobenzofuran-1(3H), 4'-piperidin]-1-yl)propyl] carbamate (578 mg) as a pale yellow oily substance.

References: [1]Patent: EP1595867,2005,A1 .Location in patent: Page/Page column 48.

7
[ 1663-39-4 ]
[ 37663-44-8 ]
[ 144-55-8 ]
[ 574741-13-2 ]

Yield	Reaction Conditions	Operation in experiment
2.77 g (98%)	With triethylamine; In tetrahydrofuran;	Preparation 21 tert-Butyl 3-(1'H, 3H-spiro[2-benzofuran-1,4'-piperidin]-1'-yl)propanoate A mixture of <strong>[37663-44-8]3H-spiro[2-benzofuran-1,4'-piperidine] hydrochloride</strong> (2.00 g, 8.86 mmol), tert-butyl acrylate (1,.36 g, 10.6 mmol), and triethylamine (1.7 ml, 12.4 mmol) in THF (20 ml) was stirred at 70° C. for 16 h. The reaction mixture was quenched with saturated aqueous NaHCO3 solution and extracted with ethyl acetate (20 ml*3). The extracts combined were washed with brine, dried (MgSO4), filtered, and concentrated. The crude product was purified by silica gel column chromatography (CH2Cl2/methanol: 20/1) to give 2.77 g (98percent) of title compound as colorless oil. 1H NMR (270 MHz, CDCl3) delta7.30-7.10 (4H, m), 5.07 (2H, s), 2.89-2.72 (4H, m), 2.52-2.40 (4H, m), 2.04-1.90 (2H, m), 1.82-1.72 (2H, m), 1.46 (9H, s).

References: [1]Patent: US2003/158219,2003,A1 .

8
[ 54596-09-7 ]
[ 37663-44-8 ]

Yield	Reaction Conditions	Operation in experiment
	With hydrogen;palladium(II) hydroxide/carbon; In methanol; at 20℃; under 760.051 Torr; for 21h;	31.0 g of 20 percent palladium hydroxide-carbon catalyst was added to methanol (1 L) solution of 227 g of the compound obtained in the above 2, and stirred in a hydrogen atmosphere at room temperature under normal pressure for 21 hours. The reaction system was purged with nitrogen, and the catalyst was removed through filtration through Celite. Then, the solvent was concentrated under reduced pressure, and the resulting white solid was taken out through filtration, washed with isopropanol and dried under reduced pressure to obtain 93.2 g of the entitled compound as a white solid. The free amine of the compound was analyzed for assignment. 1HNMR (300 MHz, CDCl3) delta: 1.89-1.92 (2H, m), 2.46 (2H, td, J=4.8, 13.8 Hz), 3.39-3.54 (4H, m), 5.09 (2H, s), 7.22-7.33 (4H, m), 9.61 (1H, brs) ESI-MS Found: m/z 189.9[M]+

References: [1]Patent: EP1726590,2006,A1 .Location in patent: Page/Page column 49-50.

9
[ 938465-47-5 ]
[ 37663-44-8 ]
[ 1132094-31-5 ]

Yield	Reaction Conditions	Operation in experiment
	With N-ethyl-N,N-diisopropylamine; In diethylene glycol dimethyl ether; at 150℃; for 96h;	4-Bromo-l-chloro-8-fluoro-5H-pyrido[4,3-]indole (150 mg, 0.501 mmol) and 3eta- spiro[2-benzofuran-l,4'-piperidinium] chloride (565 mg, 2.504 mmol) were placed in a vial and suspended in diglyme (3 mL) and Hunig'sBase (0.875 mL, 5.01 mmol). The reaction mixture was heated to 1500C for 4 days. The solution was cooled to ambient temperature, diluted with EtOAc and washed with water. The organic layer was separated, dried over magnesium sulfate, filtered and concentrated. The crude residue was purified on silica gel (EtOAc/hexanes gradient elution).

References: [1]Patent: WO2007/61764,2007,A2 .Location in patent: Page/Page column 63.

10
[ 884495-41-4 ]
[ 37663-44-8 ]
[ 1152617-83-8 ]

Yield	Reaction Conditions	Operation in experiment
63%		A solution of spiro[isobenzofuran-l(3H),4'-piperidine], hydrochloride (0.155 g, 0.818 mmol), in DCE (2 ml) was added to D41 (0.12 g, 0.682 mmol), sodium triacetoxy- borohydride (0.159 g, 0.75 mmol) and acetic acid (0.4 ml). The resulting mixture was stirred at r.t. for 1 day. The reaction mixture was diluted with NaHCO3 (aqueous sat. solution) and extracted with DCM. The organic layer was dried (MgSO4) and evaporated in vacuo. The crude product thus obtained was purified by column chromatography (silica gel; DCM/AcOEt up to 6% as eluent). The desired fractions <n="68"/>were collected and evaporated in vacuo to yield intermediate compound D44 (0.15 g, 63%) as a white solidLCMS: MW (theor): 348; [MH+]: 349; RT (min): 4.33 (Method 13)

References: [1]Patent: WO2009/62676,2009,A2 .Location in patent: Page/Page column 66-67.

11
[ 763114-26-7 ]
[ 37663-44-8 ]
[ 1174043-41-4 ]

Yield	Reaction Conditions	Operation in experiment
52.1%	With O-(1H-benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate; triethylamine; In N,N-dimethyl acetamide; at 20℃; for 5h;	Example 6 4-(4-fluoro-3-(3H-spiro[isobenzofuran-1,4'-piperidine]-1'-ylcarbonyl)benzyl)phthalazin-1(2H)-one (9) A solution of 2-fluoro-5-((4-oxo-3,4-dihydrophthalazin-1-yl)methyl)benzoic acid (1) (144 mg, 0.48 mmol) and <strong>[37663-44-8]3H-spiro[isobenzofuran-1,4'-piperidine]hydrochloride</strong> (109 mg, 0.48 mmol) in N,N-dimethylacetamide (2 mL) was treated with triethylamine (0.168 mL, 1.21 mmol) and O-Benzotriazol-1-yl-N,N,N',N'-tetra-methyluronium hexafluorophosphate (256 mg, 0.68 mmol). The resulting mixture was stirred at ambient temperature for 5 hours, before being filtered and purified by preparative HPLC (Waters XBridge Prep C18 OBD column, 5mu silica, 19 mm diameter, 100 mm length), using decreasingly polar mixtures of water (containing 0.1percent NH3) and MeCN as eluents. Fractions containing the desired compound were evaporated to dryness and lyophilised to afford the desired compound as a white solid (118 mg, 52.1percent yield); 1H NMR (400.132 MHz, DMSO) delta 1.53-1.62 (2H, m), 1.73-1.83 (3H, m), 1.91-1.99 (1H, m), 3.10-3.18 (1H, m), 4.40 (2H, s), 4.54-4.60 (1H, m), 5.03-5.11 (2H, m), 7.26-7.37 (5H, m), 7.45-7.50 (2H, m), 7.83-7.93 (2H, m), 8.02 (1H, d), 8.30 (1H, d), 12.13-12.59 (1H, br s); m/z (LC-MS, ESI+), RT=2.14 (M+H 470.9).

References: [1]Patent: US2009/192156,2009,A1 .Location in patent: Page/Page column 23.

12
[ 889865-45-6 ]
[ 37663-44-8 ]
[ 1254981-24-2 ]

Yield	Reaction Conditions	Operation in experiment
16%	With N-ethyl-N,N-diisopropylamine; In acetonitrile; at 110℃; for 16h;Sealed tube;	A mixture of DlO (1 g, 3.655 mmol), spiro[isobenzofuran-l(3H),4'-piperidine], hydrochloride [CAS 37663-44-8] (0.83 g, 4.386 mmol) and DIPEA (1.273 ml, 7.309 mmol) in CH3CN (9 ml) was heated in a sealed tube at 110 0C for 16 h. The mixture was then treated with NaHCO3 (aqueous sat. solution) and extrated with EtOAc. The organic layer was separated, dried (Na2SO4) and concentrated in vacuo. The crude product was purified by column chromatography (silica gel; DCM/EtOAc up to 2percent as eluent). The desired fractions were collected and concentrated in vacuo to yield intermediate compound D21 (0.199 g, 16percent) as a white solid. M.P. 160.80C

References: [1]Patent: WO2010/130424,2010,A1 .Location in patent: Page/Page column 103.

13
[ 1254981-17-3 ]
[ 37663-44-8 ]
[ 1254977-50-8 ]

Yield	Reaction Conditions	Operation in experiment
31%	With caesium carbonate;palladium diacetate; 2,2'-bis-(diphenylphosphino)-1,1'-binaphthyl; In toluene; at 95℃; for 16h;Sealed tube;	To a stirred solution of compound D13 (0.2 g, 0.6 mmol) in toluene (3 ml) were added spiro[isobenzofuran-l(3H),4'-piperidine] hydrochloride [CAS 37663-44-8] (0.147 g, 0.779 mmol), palladium (II) acetate (0.007 g, 0.03 mmol), Cs2CO3 (0.488 g, 1.5 mmol) and BINAP (0.028 g, 0.045 mmol). The reaction mixture was heated at 95 0C for 16 h in a sealed tube. After cooling to r.t. the mixture was diluted with EtOAc and filtered through a pad of diatomaceous earth. The filtrate was washed with NaHCO3 (aqueous sat. solution) and NaCl (aqueous sat. solution). The organic layer was separated, dried (Na2SO4) and concentrated in vacuo. The residue thus obtained was purified by column chromatography (silica gel; DCM/7M solution of NH3 in MeOH up to 1percent as eluent). The desired fractions were collected and concentrated in vacuo. The residue thus obtained was purified again by column chromatography (silica gel; DCM/EtOAc up to 60percent as eluent). The desired fractions were collected and concentrated in vacuo. The residue thus obtained was triturated with diisopropyl ether to yield final compound E6 (0.074 g, 31 percent) as a pale yellow solid.

References: [1]Patent: WO2010/130424,2010,A1 .Location in patent: Page/Page column 142-143.

14
[ 37663-44-8 ]
[ 13790-39-1 ]
C₂₂H₂₃N₃O₃ [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
	With N-ethyl-N,N-diisopropylamine; In isopropyl alcohol; at 110℃; for 0.5h;Microwave irradiation;	General procedure: Preparation of compounds V: 241, V: 243-V: 245 A sample of 3H-spiro [isobenzofuran- 1 ,4?-piperidine] hydrochloride (1.2 equiv), corresponding 4-chloro quinazolines (1 equiv.) and DIEA (2 equiv.) was taken in a microwave vial and was added i-PrOH. The reaction mixture was heated to 110 °C for 30 mm in microwave. The solvents were concentrated in vacuo, the residue partitioned between EtOAc and H20, organic layer separated, washedwith sat. brine solution, dried over anhyd. Na2SO4, solvents removed in vacuo and the crude was purified by column chromatography to obtain desiredproducts in 3 5-70percent yields.

References: [1]Patent: WO2014/127350,2014,A1 .Location in patent: Page/Page column 160.

15
[ 73831-13-7 ]
[ 37663-44-8 ]
C₂₁H₂₀N₂O₂ [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
	With N-ethyl-N,N-diisopropylamine; HATU; In N,N-dimethyl-formamide; at 20℃;	General procedure: Synthetic Schemes for compounds of formula (V)Compounds of formula (V) can be prepared according to the schemes and synthetic procedures provided below in conjunction with knowledge of the person of ordinary skill and the known disclosures of the chemical literature. Specific exemplary synthetic procedures are provided in the Examples, below. To a stirred solution of a 4-cyano-3-methylbenzoic acid (1 mmol) inDMFwas added HATU (1.3 mmol), DIPEA (2.2 mmol) and 1 mmol of spiro-4- (benzofuryl)piperidine A. The mixture was stirred overnight at r.t. and thenpoured onto water and extracted with CH2C12. The combined organic phaseswere washed with brine, dried and concentrated in vacuo. Flash chromatography afforded the title compound I.

References: [1]Patent: WO2014/127350,2014,A1 .Location in patent: Page/Page column 151; 152.

16
[ 37663-44-8 ]
[ 530-62-1 ]
C₁₆H₁₇N₃O₂ [ No CAS ]